State Street Corp Verastem, Inc. Transaction History

State Street Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$0.92 - $11.16 $37,720 - $457,560	-41,000 Reduced 5.84%	661,078 $562,000
Q2 2022 Aug 15, 2022	SELL	$1.02 - $1.83 $2.45 Million - $4.4 Million	-2,403,583 Reduced 77.39%	702,078 $814,000
Q1 2022 May 16, 2022	SELL	$1.06 - $2.1 $6.2 Million - $12.3 Million	-5,852,921 Reduced 65.33%	3,105,661 $4.38 Million
Q4 2021 Feb 14, 2022	SELL	$2.05 - $3.2 $3.39 Million - $5.3 Million	-1,655,655 Reduced 15.6%	8,958,582 $18.4 Million
Q3 2021 Nov 15, 2021	BUY	$2.54 - $4.07 $8.8 Million - $14.1 Million	3,464,644 Added 48.46%	10,614,237 $32.7 Million
Q2 2021 Aug 16, 2021	BUY	$2.57 - $4.85 $11.1 Million - $21 Million	4,335,841 Added 154.09%	7,149,593 $29.1 Million
Q1 2021 May 17, 2021	BUY	$1.9 - $2.82 $28,323 - $42,037	14,907 Added 0.53%	2,813,752 $6.95 Million
Q4 2020 Feb 16, 2021	BUY	$1.15 - $2.4 $575,382 - $1.2 Million	500,333 Added 21.77%	2,798,845 $5.96 Million
Q3 2020 Nov 10, 2020	BUY	$1.11 - $1.68 $181,759 - $275,094	163,747 Added 7.67%	2,298,512 $2.78 Million
Q2 2020 Aug 14, 2020	BUY	$1.69 - $4.2 $3.52 Million - $8.74 Million	2,081,387 Added 3899.33%	2,134,765 $3.67 Million
Q1 2020 May 11, 2020	BUY	$1.26 - $3.38 $67,256 - $180,417	53,378 New	53,378 $141,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.09B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.